Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]THK-5351 PET in Alzheimer's and Neurodegenerative Diseases
NCT02656498Phase 2Completed
- Start
- Jan 2016
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 18F-THK5351 in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI), neurodegenerative diseases. Started Jan 2016; status: completed.
02
Drugs
18F-THK5351
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)neurodegenerative diseases
Beyond the preview
Go deeper on NCT02656498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02656498.